Drug intelligence / Profile preview

RL-series

Development stage: Preclinical
Lead developer: Serpin Pharma
Modality: Peptides
Administration: Oral

Overview

RL-series is a group of oral cyclic peptide analogs currently in preclinical development by Serpin Pharma. These compounds are being investigated for the treatment of chronic kidney disease (CKD) and heart failure. Serpin Pharma specializes in developing anti-inflammatory and immune-modulating therapies, often based on the biology of serine protease inhibitors (serpins). The RL-series represents an effort to develop orally bioavailable versions of peptide-based therapeutics to address chronic inflammatory conditions.

Beyond the preview

Go deeper on RL-series.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RL-series.

Explore the full profile